06/04/2026
Why Brazil? Why now?
Global pharmaceutical companies are rethinking where they run Phase I and bioequivalence studies, and Brazil is emerging as the answer.
Clinical research costs in Brazil can be 50% to 70% lower than in the US and Europe, while quality standards remain fully aligned with FDA and EMA guidelines. For Phase I and bioequivalence (BE) studies, this cost-efficiency translates directly into faster ROI without compromising data integrity or regulatory acceptance.
Brazil delivers what few clinical trial markets can combine: a population of more than 210 million people with broad population diversity, an under-penetrated clinical research landscape (approximately 1,200 active studies versus 25,000+ in the US), and a globally recognized regulatory agency, ANVISA.
At Synvia, we provide a fully integrated, end-to-end CRO infrastructure purpose-built for Phase I and bioequivalence studies.
Over 2,000 clinical trials conducted. 162 monitored beds across fully owned clinical research sites. The largest LC-MS/MS bioanalytical facility in Latin America, with 35+ units processing more than 100,000 samples per month. CAP accredited, Cgcre/ISO 17025, ICH-GCP compliant, and audited by dozens of pharmaceutical sponsors annually.
Our integrated CRO model means a single contract covering clinical site operations, central laboratory, bioanalytical laboratory, regulatory affairs, and data intelligence, powered by our proprietary clinical trial software. No fragmented vendor chains. No coordination gaps. One trilingual point of contact from regulatory submission to final study report.
Ready to explore what Brazil can do for your project?
📩 [email protected]
